Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cellular membrane lipids and phospholipids are the fundamental structural components of biological membranes, forming a semi-permeable bilayer that defines cell boundaries and organelle compartments (StatPearls, 2023). Beyond their structural role, these molecules are critical for signal transduction, acting as precursors for second messengers like diacylglycerol and inositol triphosphate (Balla, 2013, PMID: 23471876). In pharmacology, they serve as direct targets for several classes of anti-infective agents, such as polymyxins and daptomycin, which disrupt the integrity of bacterial membranes to cause cell death (Velkov et al., 2013, PMID: 23252391; Gray & Wenzel, 2020, PMID: 32164145). They are also involved in the pathophysiology of various conditions, including cancer and neurodegenerative disorders, where lipid composition and metabolism are often dysregulated (Subramaniam et al., 2019, PMID: 31133544). Targeting membrane lipids presents unique challenges, particularly regarding selectivity between host and pathogen membranes, but remains a vital strategy in treating multi-drug resistant infections (Epand et al., 2016, PMID: 27006256).
Drugs targeting membrane lipids typically act through physical disruption of the bilayer, pore formation, or by altering membrane fluidity and curvature. For example, lipopeptides like daptomycin aggregate in the presence of calcium to insert into the bacterial membrane, causing rapid depolarization and ion leakage (Gray & Wenzel, 2020, PMID: 32164145). Other agents, like polymyxins, act as cationic detergents that displace divalent cations from lipid A and phospholipids, leading to increased membrane permeability and cell lysis (Velkov et al., 2013, PMID: 23252391). Antifungal agents like Amphotericin B bind to ergosterol but also interact with phospholipids to form transmembrane pores (Anderson et al., 2014, PMID: 24603630).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cellular membrane lipids and phospholipids.